Exogenous GH has been administrated to overcome the subjacent imbalance in GH-signaling, showing good tolerance in NS and CFC patients and some efficiency mainly during the first two years of regimen (45, 48, 67). Here, GH1 is linked to cardiofaciocutaneous syndrome.